NCT02055690 - PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 24, 2017

Study Completion Date

November 24, 2017

Conditions

Ovarian NeoplasmsNeoplasms, OvarianOvarian Cancer

Interventions

DRUG

Pazopanib

Tyrosine Kinase Inhibitor

DRUG

Fosbretabulin

Vascular Disrupting Agent

Trial Locations (10)

Royal United Hospital Bath NHS Trust, Bath

City Hospital, Birmingham

University Hospitals Bristol NHS Foundation Trust, Bristol

University Collage London Hospitals NHS Foundation Trust, London

The Royal Marsden NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester

Clatterbridge Centre for Oncology NHS Foundation Trust, Metropolitan Borough of Wirral

Mount Vernon Cancer Centre (East and North Herts NHS Trust), Middlesex

Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle upon Tyne

Oxford Radcliffe Hospitals NHS Trust, Oxford